candesartan has been researched along with Elevated Cholesterol in 8 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin (RSV) compared with CND or RSV monotherapy in patients with hypertension and hypercholesterolemia." | 9.30 | Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. ( Ahn, JC; Ahn, SH; Chang, K; Cho, KI; Chung, WJ; Gyu Park, C; Hong, BK; Hong, TJ; Kim, BH; Kim, SH; Kim, SY; Kim, W; Kim, YJ; Lee, JY; Park, YH; Ryu, JK; Shin, JH; Sohn, IS; Yu, CW, 2019) |
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 9.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| "The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin (RSV) compared with CND or RSV monotherapy in patients with hypertension and hypercholesterolemia." | 5.30 | Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. ( Ahn, JC; Ahn, SH; Chang, K; Cho, KI; Chung, WJ; Gyu Park, C; Hong, BK; Hong, TJ; Kim, BH; Kim, SH; Kim, SY; Kim, W; Kim, YJ; Lee, JY; Park, YH; Ryu, JK; Shin, JH; Sohn, IS; Yu, CW, 2019) |
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 5.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| "Treatment with cerivastatin did not affect the response to Ang II compared with baseline." | 2.71 | The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men. ( Delles, C; Fleischmann, EH; John, S; Schmidt, BM; Schmieder, RE; Schneider, MP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, KI | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Ahn, JC | 1 |
| Kim, SH | 1 |
| Chung, WJ | 1 |
| Kim, W | 1 |
| Sohn, IS | 1 |
| Shin, JH | 1 |
| Kim, YJ | 1 |
| Chang, K | 1 |
| Yu, CW | 1 |
| Ahn, SH | 1 |
| Kim, SY | 1 |
| Ryu, JK | 1 |
| Lee, JY | 1 |
| Hong, BK | 1 |
| Hong, TJ | 1 |
| Gyu Park, C | 1 |
| Torres, RJ | 1 |
| Luchini, A | 1 |
| Torres, Rdo R | 1 |
| Oliveira, LR | 1 |
| Torres, CL | 1 |
| Torres, RA | 1 |
| Olandoski, M | 1 |
| Nagashima, S | 1 |
| Noronha, Ld | 1 |
| Precoma, DB | 1 |
| Wassmann, S | 1 |
| Hilgers, S | 1 |
| Laufs, U | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| Fleischmann, EH | 1 |
| John, S | 1 |
| Delles, C | 1 |
| Schneider, MP | 1 |
| Schmidt, BM | 1 |
| Schmieder, RE | 1 |
| Chang, A | 1 |
| Logar, CM | 1 |
| Finn, LS | 1 |
| Alpers, CE | 1 |
| Seliger, SL | 1 |
| Usher-Smith, JA | 1 |
| Ramsbottom, T | 2 |
| Pearmain, H | 2 |
| Kirby, M | 2 |
| Omasu, F | 1 |
| Oda, T | 1 |
| Yamada, M | 1 |
| Yoshizawa, N | 1 |
| Yamakami, K | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Usher-Smith, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.[NCT02770261] | Phase 3 | 219 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for candesartan and Elevated Cholesterol
| Article | Year |
|---|---|
Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Meth | 2019 |
Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biomarker | 2002 |
The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.
Topics: Adolescent; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarke | 2004 |
5 other studies available for candesartan and Elevated Cholesterol
| Article | Year |
|---|---|
Effect of candesartan on the expression of sclera-choroidal intercellular adhesion molecule-1 in hypercholesterolemic models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Choroid; Disea | 2014 |
A rare cause of necrotizing and crescentic glomerulonephritis in a young adult male.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autoa | 2005 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Ben | 2007 |
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Disease Models | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidaz | 2008 |